HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Small-molecule MDM2 inhibitor LQFM030-induced apoptosis in p53-null K562 chronic myeloid leukemia cells.

Abstract
Our group designed and synthesized the N-phenyl-piperazine LQFM030 [1-(4-((1-(4-chlorophenyl)-1H-pyrazol-4-yl)methyl) piperazin-1-yl) ethanone], a small molecule derived from molecular simplification of the Nutlin-1, an inhibitor of the human homologue of murine double minute 2 (MDM2) protein that is expressed in several types of cancer. To better investigate the effects of LQFM030 regarding the p53 mutation status, this study investigated the antiproliferative activity of LQFM030 against the p53-null K562 leukemia cells as well as the cell death pathways involved. In addition, the effects of LQFM030 on the levels of the p53/MDM2 complex were also carried out using 3T3 cells as a p53 wild-type model. Our data suggest that LQFM030 triggered apoptosis in K562 cells via different mechanisms including cell cycle arrest, caspase activation, reduction of mitochondrial activity, decrease in MDM2 expression, and transcriptional modulation of MDMX, p73, MYC, and NF-ĸB. Additionally, it promoted effects in p53/MDM2 binding in p53 wild-type 3T3 cells. Therefore, LQFM030 has antiproliferative effects in cancer cells by a p53 mutation status-independent manner with different signaling pathways. These findings open new perspectives to the treatment of leukemic cells considering the resistance development associated with cancer treatment with conventional cytotoxic drugs.
AuthorsHigor de Oliveira Ribeiro, Alane Pereira Cortez, Renato Ivan de Ávila, Artur Christian Garcia da Silva, Flávio Silva de Carvalho, Ricardo Menegatti, Luciano Morais Lião, Marize Campos Valadares
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 34 Issue 4 Pg. 444-457 (Aug 2020) ISSN: 1472-8206 [Electronic] England
PMID32011031 (Publication Type: Journal Article)
Copyright© 2020 Société Française de Pharmacologie et de Thérapeutique.
Chemical References
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Enzyme Inhibitors
  • LQFM030
  • Piperidines
  • Pyrazoles
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Apoptosis (drug effects)
  • Apoptosis Regulatory Proteins (genetics, metabolism)
  • BALB 3T3 Cells
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, enzymology, genetics, pathology)
  • Mice
  • Mutation
  • Piperidines (pharmacology)
  • Proto-Oncogene Proteins c-mdm2 (antagonists & inhibitors, metabolism)
  • Pyrazoles (pharmacology)
  • Signal Transduction
  • Tumor Suppressor Protein p53 (deficiency, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: